Direct measure of the de novo mutation rate in autism and schizophrenia cohorts

Philip Awadalla, Julie Gauthier, Rachel A. Myers, Ferran Casals, Fadi F. Hamdan, Alexander R. Griffing, Mélanie Côté, Edouard Henrion, Dan Spiegelman, Julien Tarabeux, Amélie Piton, Yan Yang, Adam Boyko, Carlos Bustamante, Lan Xiong, Judith L. Rapoport, Anjené M. Addington, J. Lynn E Delisi, Marie Odile Krebs, Ridha JooberBruno Millet, Eric Fombonne, Laurent Mottron, Martine Zilversmit, Jon Keebler, Hussein Daoud, Claude Marineau, Marie Hélne Roy-Gagnon, Marie Pierre Dubé, Adam Eyre-Walker, Pierre Drapeau, Eric A. Stone, Ronald G. Lafrenire, Guy A. Rouleau

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

The role of de novo mutations (DNMs) in common diseases remains largely unknown. Nonetheless, the rate of de novo deleterious mutations and the strength of selection against de novo mutations are critical to understanding the genetic architecture of a disease. Discovery of high-impact DNMs requires substantial high-resolution interrogation of partial or complete genomes of families via resequencing. We hypothesized that deleterious DNMs may play a role in cases of autism spectrum disorders (ASD) and schizophrenia (SCZ), two etiologically heterogeneous disorders with significantly reduced reproductive fitness. We present a direct measure of the de novo mutation rate (μ) and selective constraints from DNMs estimated from a deep resequencing data set generated from a large cohort of ASD and SCZ cases (n = 285) and population control individuals (n = 285) with available parental DNA. A survey of ∼430 Mb of DNA from 401 synapse-expressed genes across all cases and 25 Mb of DNA in controls found 28 candidate DNMs, 13 of which were cell line artifacts. Our calculated direct neutral mutation rate (1.36 × 10-8) is similar to previous indirect estimates, but we observed a significant excess of potentially deleterious DNMs in ASD and SCZ individuals. Our results emphasize the importance of DNMs as genetic mechanisms in ASD and SCZ and the limitations of using DNA from archived cell lines to identify functional variants.

Original languageEnglish (US)
Pages (from-to)316-324
Number of pages9
JournalAmerican Journal of Human Genetics
Volume87
Issue number3
DOIs
StatePublished - Sep 10 2010
Externally publishedYes

Fingerprint

Mutation Rate
Autistic Disorder
Schizophrenia
Mutation
DNA
Genetic Fitness
Cell Line
Population Control
Synapses
Artifacts
Genome
Autism Spectrum Disorder

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Medicine(all)

Cite this

Awadalla, P., Gauthier, J., Myers, R. A., Casals, F., Hamdan, F. F., Griffing, A. R., ... Rouleau, G. A. (2010). Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. American Journal of Human Genetics, 87(3), 316-324. https://doi.org/10.1016/j.ajhg.2010.07.019

Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. / Awadalla, Philip; Gauthier, Julie; Myers, Rachel A.; Casals, Ferran; Hamdan, Fadi F.; Griffing, Alexander R.; Côté, Mélanie; Henrion, Edouard; Spiegelman, Dan; Tarabeux, Julien; Piton, Amélie; Yang, Yan; Boyko, Adam; Bustamante, Carlos; Xiong, Lan; Rapoport, Judith L.; Addington, Anjené M.; Delisi, J. Lynn E; Krebs, Marie Odile; Joober, Ridha; Millet, Bruno; Fombonne, Eric; Mottron, Laurent; Zilversmit, Martine; Keebler, Jon; Daoud, Hussein; Marineau, Claude; Roy-Gagnon, Marie Hélne; Dubé, Marie Pierre; Eyre-Walker, Adam; Drapeau, Pierre; Stone, Eric A.; Lafrenire, Ronald G.; Rouleau, Guy A.

In: American Journal of Human Genetics, Vol. 87, No. 3, 10.09.2010, p. 316-324.

Research output: Contribution to journalArticle

Awadalla, P, Gauthier, J, Myers, RA, Casals, F, Hamdan, FF, Griffing, AR, Côté, M, Henrion, E, Spiegelman, D, Tarabeux, J, Piton, A, Yang, Y, Boyko, A, Bustamante, C, Xiong, L, Rapoport, JL, Addington, AM, Delisi, JLE, Krebs, MO, Joober, R, Millet, B, Fombonne, E, Mottron, L, Zilversmit, M, Keebler, J, Daoud, H, Marineau, C, Roy-Gagnon, MH, Dubé, MP, Eyre-Walker, A, Drapeau, P, Stone, EA, Lafrenire, RG & Rouleau, GA 2010, 'Direct measure of the de novo mutation rate in autism and schizophrenia cohorts', American Journal of Human Genetics, vol. 87, no. 3, pp. 316-324. https://doi.org/10.1016/j.ajhg.2010.07.019
Awadalla P, Gauthier J, Myers RA, Casals F, Hamdan FF, Griffing AR et al. Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. American Journal of Human Genetics. 2010 Sep 10;87(3):316-324. https://doi.org/10.1016/j.ajhg.2010.07.019
Awadalla, Philip ; Gauthier, Julie ; Myers, Rachel A. ; Casals, Ferran ; Hamdan, Fadi F. ; Griffing, Alexander R. ; Côté, Mélanie ; Henrion, Edouard ; Spiegelman, Dan ; Tarabeux, Julien ; Piton, Amélie ; Yang, Yan ; Boyko, Adam ; Bustamante, Carlos ; Xiong, Lan ; Rapoport, Judith L. ; Addington, Anjené M. ; Delisi, J. Lynn E ; Krebs, Marie Odile ; Joober, Ridha ; Millet, Bruno ; Fombonne, Eric ; Mottron, Laurent ; Zilversmit, Martine ; Keebler, Jon ; Daoud, Hussein ; Marineau, Claude ; Roy-Gagnon, Marie Hélne ; Dubé, Marie Pierre ; Eyre-Walker, Adam ; Drapeau, Pierre ; Stone, Eric A. ; Lafrenire, Ronald G. ; Rouleau, Guy A. / Direct measure of the de novo mutation rate in autism and schizophrenia cohorts. In: American Journal of Human Genetics. 2010 ; Vol. 87, No. 3. pp. 316-324.
@article{739fa58a0daf4df19a3469bbab7b5275,
title = "Direct measure of the de novo mutation rate in autism and schizophrenia cohorts",
abstract = "The role of de novo mutations (DNMs) in common diseases remains largely unknown. Nonetheless, the rate of de novo deleterious mutations and the strength of selection against de novo mutations are critical to understanding the genetic architecture of a disease. Discovery of high-impact DNMs requires substantial high-resolution interrogation of partial or complete genomes of families via resequencing. We hypothesized that deleterious DNMs may play a role in cases of autism spectrum disorders (ASD) and schizophrenia (SCZ), two etiologically heterogeneous disorders with significantly reduced reproductive fitness. We present a direct measure of the de novo mutation rate (μ) and selective constraints from DNMs estimated from a deep resequencing data set generated from a large cohort of ASD and SCZ cases (n = 285) and population control individuals (n = 285) with available parental DNA. A survey of ∼430 Mb of DNA from 401 synapse-expressed genes across all cases and 25 Mb of DNA in controls found 28 candidate DNMs, 13 of which were cell line artifacts. Our calculated direct neutral mutation rate (1.36 × 10-8) is similar to previous indirect estimates, but we observed a significant excess of potentially deleterious DNMs in ASD and SCZ individuals. Our results emphasize the importance of DNMs as genetic mechanisms in ASD and SCZ and the limitations of using DNA from archived cell lines to identify functional variants.",
author = "Philip Awadalla and Julie Gauthier and Myers, {Rachel A.} and Ferran Casals and Hamdan, {Fadi F.} and Griffing, {Alexander R.} and M{\'e}lanie C{\^o}t{\'e} and Edouard Henrion and Dan Spiegelman and Julien Tarabeux and Am{\'e}lie Piton and Yan Yang and Adam Boyko and Carlos Bustamante and Lan Xiong and Rapoport, {Judith L.} and Addington, {Anjen{\'e} M.} and Delisi, {J. Lynn E} and Krebs, {Marie Odile} and Ridha Joober and Bruno Millet and Eric Fombonne and Laurent Mottron and Martine Zilversmit and Jon Keebler and Hussein Daoud and Claude Marineau and Roy-Gagnon, {Marie H{\'e}lne} and Dub{\'e}, {Marie Pierre} and Adam Eyre-Walker and Pierre Drapeau and Stone, {Eric A.} and Lafrenire, {Ronald G.} and Rouleau, {Guy A.}",
year = "2010",
month = "9",
day = "10",
doi = "10.1016/j.ajhg.2010.07.019",
language = "English (US)",
volume = "87",
pages = "316--324",
journal = "American Journal of Human Genetics",
issn = "0002-9297",
publisher = "Cell Press",
number = "3",

}

TY - JOUR

T1 - Direct measure of the de novo mutation rate in autism and schizophrenia cohorts

AU - Awadalla, Philip

AU - Gauthier, Julie

AU - Myers, Rachel A.

AU - Casals, Ferran

AU - Hamdan, Fadi F.

AU - Griffing, Alexander R.

AU - Côté, Mélanie

AU - Henrion, Edouard

AU - Spiegelman, Dan

AU - Tarabeux, Julien

AU - Piton, Amélie

AU - Yang, Yan

AU - Boyko, Adam

AU - Bustamante, Carlos

AU - Xiong, Lan

AU - Rapoport, Judith L.

AU - Addington, Anjené M.

AU - Delisi, J. Lynn E

AU - Krebs, Marie Odile

AU - Joober, Ridha

AU - Millet, Bruno

AU - Fombonne, Eric

AU - Mottron, Laurent

AU - Zilversmit, Martine

AU - Keebler, Jon

AU - Daoud, Hussein

AU - Marineau, Claude

AU - Roy-Gagnon, Marie Hélne

AU - Dubé, Marie Pierre

AU - Eyre-Walker, Adam

AU - Drapeau, Pierre

AU - Stone, Eric A.

AU - Lafrenire, Ronald G.

AU - Rouleau, Guy A.

PY - 2010/9/10

Y1 - 2010/9/10

N2 - The role of de novo mutations (DNMs) in common diseases remains largely unknown. Nonetheless, the rate of de novo deleterious mutations and the strength of selection against de novo mutations are critical to understanding the genetic architecture of a disease. Discovery of high-impact DNMs requires substantial high-resolution interrogation of partial or complete genomes of families via resequencing. We hypothesized that deleterious DNMs may play a role in cases of autism spectrum disorders (ASD) and schizophrenia (SCZ), two etiologically heterogeneous disorders with significantly reduced reproductive fitness. We present a direct measure of the de novo mutation rate (μ) and selective constraints from DNMs estimated from a deep resequencing data set generated from a large cohort of ASD and SCZ cases (n = 285) and population control individuals (n = 285) with available parental DNA. A survey of ∼430 Mb of DNA from 401 synapse-expressed genes across all cases and 25 Mb of DNA in controls found 28 candidate DNMs, 13 of which were cell line artifacts. Our calculated direct neutral mutation rate (1.36 × 10-8) is similar to previous indirect estimates, but we observed a significant excess of potentially deleterious DNMs in ASD and SCZ individuals. Our results emphasize the importance of DNMs as genetic mechanisms in ASD and SCZ and the limitations of using DNA from archived cell lines to identify functional variants.

AB - The role of de novo mutations (DNMs) in common diseases remains largely unknown. Nonetheless, the rate of de novo deleterious mutations and the strength of selection against de novo mutations are critical to understanding the genetic architecture of a disease. Discovery of high-impact DNMs requires substantial high-resolution interrogation of partial or complete genomes of families via resequencing. We hypothesized that deleterious DNMs may play a role in cases of autism spectrum disorders (ASD) and schizophrenia (SCZ), two etiologically heterogeneous disorders with significantly reduced reproductive fitness. We present a direct measure of the de novo mutation rate (μ) and selective constraints from DNMs estimated from a deep resequencing data set generated from a large cohort of ASD and SCZ cases (n = 285) and population control individuals (n = 285) with available parental DNA. A survey of ∼430 Mb of DNA from 401 synapse-expressed genes across all cases and 25 Mb of DNA in controls found 28 candidate DNMs, 13 of which were cell line artifacts. Our calculated direct neutral mutation rate (1.36 × 10-8) is similar to previous indirect estimates, but we observed a significant excess of potentially deleterious DNMs in ASD and SCZ individuals. Our results emphasize the importance of DNMs as genetic mechanisms in ASD and SCZ and the limitations of using DNA from archived cell lines to identify functional variants.

UR - http://www.scopus.com/inward/record.url?scp=77956392692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956392692&partnerID=8YFLogxK

U2 - 10.1016/j.ajhg.2010.07.019

DO - 10.1016/j.ajhg.2010.07.019

M3 - Article

C2 - 20797689

AN - SCOPUS:77956392692

VL - 87

SP - 316

EP - 324

JO - American Journal of Human Genetics

JF - American Journal of Human Genetics

SN - 0002-9297

IS - 3

ER -